 Chemoprotective effects recombinant human alpha cyclophosphamide-treated normal tumor-bearing mice Protection acute toxicity hematologic effects development late mortality therapeutic efficacy study recombinant human alpha alpha normal tumor-bearing BALB/c mice acute toxicity lethal doses cyclophosphamide Cy Pretreatment mice days U/day alpha mice acute death lethal doses Cy mg/kg mg/kg contrast post-treatment mice single multiple doses alpha chemoprotective Pretreatment mice alpha acute Cy mg/kg mg/kg normal mice dose-modifying effect rapid recovery neutropenia severe reduction number bone marrow single lineage monocyte myeloid myelomonocytic colonies mice pretreatment alpha day mice extensive pulmonary inflammation fibrosis death Mice murine renal cancer Renca acute toxic effects Cy mg/kg pretreatment alpha Renca-bearing mice alpha sublethal mg/kg lethal mg/kg Cy survival times untreated Renca-bearing mice cause death Renca-bearing mice treatment alpha mg/kg Cy recurrent tumor mice alpha mg/kg Cy detectable tumor several late pulmonary inflammation fibrosis dose escalation Cy alpha-pretreated mice results antitumor effects Cy dose escalation cytotoxic agents use myelostimulatory agents late fatal complications acute toxicity testing